E2022 Patch Formulation Single Dose Phase I Study.

Trial Profile

E2022 Patch Formulation Single Dose Phase I Study.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2016

At a glance

  • Drugs Donepezil (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 11 Aug 2011 Additional lead trial investigator (Tomoo Ogawa) identified as reported by ClinicalTrials.gov.
    • 11 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top